RPG Life Sciences PEG
The PEG Ratio (Price/Earnings-to-Growth) of RPG Life Sciences (RPGLIFE.NS) as of Nov 4, 2026 is 1.35. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 0.85 — a change of 59.10% (higher).
Get this data via API
Financial Data API
PEG
1.35
YoY
59.10%
Last updated:
The RPG Life Sciences PEG history
3 Years
10 Years
25 Years
Max
| YEAR | PEG | YoY |
|---|---|---|
| 1.35 | +59.10% | |
| 0.85 | -52.16% | |
| 1.77 | -22.84% | |
| 2.29 | -23.89% | |
| 3.01 | -22.30% | |
| 3.88 | -27.48% | |
| 5.35 | -62.74% | |
| 14.35 | +24.42% | |
| 11.54 | +52.12% | |
| 7.58 | -43.21% | |
| 13.35 | -91.39% | |
| 155.16 | +5,240.00% | |
| 2.91 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
RPG Life Sciences Stock analysis
Frequently Asked Questions about RPG Life Sciences stock
PEG Ratio (Price/Earnings-to-Growth) of RPG Life Sciences is 1.35 in 2026.
PEG Ratio (Price/Earnings-to-Growth) of RPG Life Sciences changed from 0.85 to 1.35, representing a 59.10% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) RPG Life Sciences since 2006 – with annual values, charts, and detailed analysis.
The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.
PEG = P/E Ratio / Expected Annual EPS Growth Rate
To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).
A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s RPG Life Sciences with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Valuation — RPG Life Sciences
All Key Metrics — RPG Life Sciences
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth